Hematology News

Boston Scientific announced it received FDA 510(k) clearance for its embolization device with a fibered detachable coil, indicated to obstruct or reduce blood flow in the peripheral vasculature.

WASHINGTON — In patients with atrial fibrillation requiring stroke prevention, the novel factor XIa inhibitor asundexian was associated with lower bleeding rates compared with apixaban, according to the results of the PACIFIC-AF trial.

Exposure to systemic corticosteroids appeared to increase risk for hospitalization for vaso-occlusive episodes among patients with sickle cell disease, according to a French study published in Blood.

SALT LAKE CITY — Prevalence of organ dysfunction appeared low among pediatric patients who underwent hematopoietic stem cell transplantation for sickle cell disease, according to retrospective study results.

SALT LAKE CITY — Sickle cell disease increased risk for transplant-associated thrombotic microangiopathy among children who underwent hematopoietic stem cell transplantation, according to study results.

Most male adolescents and young adults with sickle cell disease reported a desire to have children later in life but few knew of disease-related fertility issues, according to study results published in Blood Advances.

In a video interview with Healio, Michael Auerbach, MD, FACP, discussed the importance of managing iron deficiency anemia — which he described as the most common “malady on the planet” — in pregnancy.

Direct oral anticoagulants significantly reduced risk for recurrence of cancer-associated venous thromboembolism compared with dalteparin among patients with cancer, according to study results published in Mayo Clinic Proceedings.

With the aid of $17 million in grant funding, UCSF Benioff Children’s Hospital Oakland will initiate a 4-year trial evaluating CRISPR/Cas9 gene editing as a potential cure for sickle cell disease.

Rilzabrutinib induced rapid and durable clinical activity in previously treated patients with immune thrombocytopenia, according to results of a phase 1/phase 2 clinical trial published in The New England Journal of Medicine.